WO2005116260A3 - Influenza hemagglutinin and neuraminidase variants - Google Patents

Influenza hemagglutinin and neuraminidase variants Download PDF

Info

Publication number
WO2005116260A3
WO2005116260A3 PCT/US2005/017733 US2005017733W WO2005116260A3 WO 2005116260 A3 WO2005116260 A3 WO 2005116260A3 US 2005017733 W US2005017733 W US 2005017733W WO 2005116260 A3 WO2005116260 A3 WO 2005116260A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza hemagglutinin
neuraminidase variants
neuraminidase
variants
hemagglutinin
Prior art date
Application number
PCT/US2005/017733
Other languages
French (fr)
Other versions
WO2005116260A2 (en
Inventor
Chin-Fen Yang
George Kemble
Kanta Subbarao
Brian Murphy
Original Assignee
Medimmune Vaccines Inc
Us Gov Nat Inst Health
Chin-Fen Yang
George Kemble
Kanta Subbarao
Brian Murphy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Vaccines Inc, Us Gov Nat Inst Health, Chin-Fen Yang, George Kemble, Kanta Subbarao, Brian Murphy filed Critical Medimmune Vaccines Inc
Priority to ES05751982T priority Critical patent/ES2393492T3/en
Priority to AU2005248377A priority patent/AU2005248377B2/en
Priority to CA2568020A priority patent/CA2568020C/en
Priority to EP05751982A priority patent/EP1766059B1/en
Priority to JP2007515200A priority patent/JP4980896B2/en
Publication of WO2005116260A2 publication Critical patent/WO2005116260A2/en
Publication of WO2005116260A3 publication Critical patent/WO2005116260A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Abstract

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
PCT/US2005/017733 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants WO2005116260A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES05751982T ES2393492T3 (en) 2004-05-25 2005-05-20 Variants of hemagglutinin and influenza neuraminidase
AU2005248377A AU2005248377B2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants
CA2568020A CA2568020C (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants
EP05751982A EP1766059B1 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants
JP2007515200A JP4980896B2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57455304P 2004-05-25 2004-05-25
US60/574,553 2004-05-25
US65755405P 2005-02-28 2005-02-28
US60/657,554 2005-02-28

Publications (2)

Publication Number Publication Date
WO2005116260A2 WO2005116260A2 (en) 2005-12-08
WO2005116260A3 true WO2005116260A3 (en) 2009-02-26

Family

ID=35451479

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/017733 WO2005116260A2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase variants
PCT/US2005/017729 WO2005116258A2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase varians

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017729 WO2005116258A2 (en) 2004-05-25 2005-05-20 Influenza hemagglutinin and neuraminidase varians

Country Status (8)

Country Link
US (6) US7504109B2 (en)
EP (6) EP2530147B1 (en)
JP (2) JP4980895B2 (en)
AU (3) AU2005248375B2 (en)
CA (4) CA2568020C (en)
ES (5) ES2525672T3 (en)
HK (1) HK1179648A1 (en)
WO (2) WO2005116260A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
EP2581093B1 (en) 2003-06-16 2015-03-18 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
US9254315B2 (en) * 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
ES2525672T3 (en) * 2004-05-25 2014-12-29 Medimmune, Llc Variants of hemagglutinin and influenza neuraminidase
AU2011202991B2 (en) * 2004-05-25 2012-12-20 Medlmmune, Llc Influenza hemagglutinin and neuraminidase variants
EP1826269B1 (en) 2004-11-01 2012-04-04 Eiken Kagaku Kabushiki Kaisha Method of detecting h5 avian influenza virus
BRPI0518728A2 (en) * 2004-12-09 2008-12-02 Univ Pittsburgh vaccines for rapid response to avian influenza pandemic
EP1856271A4 (en) 2005-03-08 2009-11-18 Medimmune Vaccines Inc Influenza hemagglutinin and neuraminidase variants
EP1919504B1 (en) * 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
BRPI0618254A2 (en) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic free aqueous phase surfactant emulsions to provide adjuvant to split influenza vaccines
GEP20135924B (en) 2005-12-02 2013-10-10 The Mount Sinai School Of Medicine Of New York Univ Chimeric viruses presenting non-native surface proteins and usage thereof
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
JP2009526526A (en) * 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド Influenza antigens, vaccine compositions, and related methods
EP1991700B1 (en) 2006-02-13 2012-01-11 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Primers and probes for detection and discrimination of types and subtypes of influenza viruses
US20080279877A1 (en) * 2006-02-13 2008-11-13 Fraunhofer U.S.A. Inc. HPV antigens, vaccine compositions, and related methods
RU2318871C1 (en) * 2006-04-19 2008-03-10 ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН /ГУ НИИЭМ РАМН/ Strain of influenza virus gkv 2389 for production of living intranasal and inactivated influenza vaccine
EP2029167A4 (en) * 2006-06-16 2010-06-16 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
US20080003203A1 (en) * 2006-06-28 2008-01-03 National Tsing Hua University Pseudotyped baculovirus to stimulate immunogenicity against avian influenza
JP2010500034A (en) * 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド Influenza hemagglutinin mutant and neuraminidase mutant
AU2013206611B2 (en) * 2006-08-09 2016-01-14 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2008134643A2 (en) * 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
KR101466326B1 (en) * 2007-06-15 2014-12-02 주식회사 바이오트라이온 An attenuated influenza virus and a live vaccine comprising the same
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
US20110059130A1 (en) * 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
US8470771B2 (en) * 2007-11-14 2013-06-25 Institute Of Microbiology, Chinese Academy Of Sciences Method and medicament for inhibiting the infection of influenza virus
CA2730408A1 (en) * 2008-07-11 2010-01-14 Chin-Fen Yang Influenza hemagglutinin and neuraminidase variants
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
CN107365751B (en) 2008-12-16 2021-07-09 纳米医疗公司 Production of influenza vaccines
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
BRPI1008549A2 (en) * 2009-02-12 2016-03-15 Medimmune Llc influenza neuraminidase and hemagglutinin variants
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
MX2011010406A (en) * 2009-04-03 2012-01-20 Merial Ltd Newcastle disease virus vectored avian vaccines.
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
JP5854559B2 (en) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド Method for preparing vesicles and preparations produced therefrom
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
CA2785971C (en) * 2009-12-28 2019-02-12 Dsm Ip Assets B.V. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
EA030095B1 (en) * 2009-12-28 2018-06-29 ДиЭсЭм АйПи АССЕТС Б.В. Production of hemagglutinin-neuraminidase protein in microalgae
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
US9701723B2 (en) * 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
US8513006B2 (en) 2010-09-14 2013-08-20 University of Pittsburgh—of the Commonwealth System of Higher Education Tetravalent influenza vaccine and use thereof
AU2011312178B2 (en) 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2012061239A2 (en) * 2010-11-02 2012-05-10 Opko Pharmaceuticals, Llc Novel vaccines against pandemic influenza virus a/h1n1
BR112013010830A2 (en) * 2010-11-02 2017-12-12 Hector Manuel Zepeda Lopez Innovative vaccine against the pandemic influenza a / h1n1 virus
MX357319B (en) 2011-01-13 2018-07-04 Variation Biotechnologies Inc Methods for preparing vesicles and formulations produced therefrom.
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AR088028A1 (en) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed PROTEINS H5, FROM H5N1 FOR MEDICINAL USE
CN102304495A (en) * 2011-09-08 2012-01-04 中国农业科学院上海兽医研究所 Recombinant influenza virus capable of expressing HA (hemagglutinin) protein with high efficiency and preparation method and application thereof
MX2014003308A (en) 2011-09-20 2015-03-09 Sinai School Medicine Influenza virus vaccines and uses thereof.
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Compositions and methods for treating viral infections
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
KR101481986B1 (en) * 2012-07-23 2015-01-19 연세대학교 산학협력단 Live vaccine protecting against pathogenic avian influenza H5N1 and use thereof
CN108641002A (en) 2012-12-18 2018-10-12 西奈山伊坎医学院 Influenza virus vaccine and application thereof
MX360137B (en) * 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament.
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP2969005B1 (en) 2013-03-15 2019-10-16 The Research Foundation for The State University of New York Attenuated influenza viruses and vaccines
US10006097B2 (en) 2013-10-22 2018-06-26 The United States of America, as represented by the Secretry, Department of Health and Human Services Compositions and methods for detection and discrimination of influenza viruses
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP7237344B2 (en) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ Influenza virus hemagglutinin protein and uses thereof
CN106939355A (en) * 2017-03-01 2017-07-11 苏州系统医学研究所 A kind of screening of influenza virus attenuated live vaccines strain and authentication method
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JP7329530B2 (en) * 2018-03-28 2023-08-18 サノフィ パスツール インコーポレイテッド Methods of producing broadly protective vaccine compositions containing neuraminidase
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021263282A1 (en) * 2020-06-24 2021-12-30 Trustees Of Tufts College Edible cell based vaccines
CN113150083B (en) * 2021-04-29 2023-03-24 山西高等创新研究院 Recombinant avian influenza subunit vaccine and preparation method thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US3992522A (en) * 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US4071618A (en) * 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US4656569A (en) * 1985-10-22 1987-04-07 Hugh Buskell Elevating apparatus particularly for the canopy of a lamp standard
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
WO1993021306A1 (en) 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Genetically engineered attenuated viruses
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Attenuated respiratory syncytial virus vaccine compositions
CA2110242C (en) * 1992-11-27 2001-01-23 Masayoshi Aihara Portable facsimile equipment
DE4301103C1 (en) * 1993-01-18 1994-08-18 Voith Gmbh J M Screen section of a paper machine
US7094597B1 (en) * 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
ES2210273T5 (en) * 1994-07-18 2010-03-29 Conzelmann, Karl-Klaus, Prof. Dr. VIRUS WITH NEGATIVE CHAIN NON-SEGMENTED RECOMBINANT INFECTIVE.
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DK0780475T4 (en) 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Method of producing infectious negative-strand RNA virus
WO1997012032A1 (en) 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
KR100754091B1 (en) 1995-10-31 2007-08-31 가부시끼가이샤 디나벡 겡뀨쇼 (-)-strand RNA virus vector having autonomously replicating activity
WO1997016539A1 (en) 1995-11-01 1997-05-09 Dnavec Research Inc. Recombinant sendai virus
US6090391A (en) * 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
AU4427897A (en) 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
EP0994949B1 (en) 1997-05-23 2011-03-09 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
ES2287977T3 (en) 1997-07-11 2007-12-16 Yale University RABDOVIRUS WITH REDISED COVERS.
WO1999015672A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
EP1035209A1 (en) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
KR100702275B1 (en) 1999-04-06 2007-03-30 위스콘신 얼럼나이 리서어치 화운데이션 Recombinant influenza viruses for vaccines and gene therapy
WO2001064860A2 (en) 2000-03-02 2001-09-07 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses
ATE420189T1 (en) * 2000-04-28 2009-01-15 St Jude Childrens Res Hospital DNA TRANSFECTION SYSTEM FOR GENERATING INFECTIOUS NEGATIVE STRAND RNA VIRUS
KR100927517B1 (en) * 2000-09-25 2009-11-17 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 Live vaccine
USPP15035P3 (en) * 2001-06-27 2004-07-27 Marko Zaninovich, Inc. Grapevine ‘12-76-71’
KR100600988B1 (en) 2002-03-13 2006-07-13 주식회사 엘지생명과학 Method for enhancing immune responses by codelivering influenza NP DNA in DNA immunization
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
KR101229202B1 (en) * 2002-04-26 2013-02-01 메디뮨 엘엘씨 Multi plasmid system for the production of influenza virus
EP2581093B1 (en) * 2003-06-16 2015-03-18 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
WO2005042700A2 (en) * 2003-10-20 2005-05-12 The Johns Hopkins University Use of hedgehog pathway inhibitors in small-cell lung cancer
ES2525672T3 (en) * 2004-05-25 2014-12-29 Medimmune, Llc Variants of hemagglutinin and influenza neuraminidase
EP1826269B1 (en) 2004-11-01 2012-04-04 Eiken Kagaku Kabushiki Kaisha Method of detecting h5 avian influenza virus
EP1856271A4 (en) * 2005-03-08 2009-11-18 Medimmune Vaccines Inc Influenza hemagglutinin and neuraminidase variants
JP2010500034A (en) * 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド Influenza hemagglutinin mutant and neuraminidase mutant
WO2009014919A2 (en) 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
BRPI1008549A2 (en) * 2009-02-12 2016-03-15 Medimmune Llc influenza neuraminidase and hemagglutinin variants

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 21 May 2004 (2004-05-21), "Influenza A virus (A/little grebe/Thailand/Phichit-01/2004 (H5N1) hemagglutin (HA) gene, partial cds", XP008112354, Database accession no. AY553802 *
DE, BK ET AL: "Complete sequence of cDNA clone of the hemagglutinin gene of influenza A/Chicken/Scotland/59 (H5N1) virus: comparison with contemporary North American and European strains", NUCLEIC ACIDS RESEARCH, vol. 16, no. 9, 1988, pages 4181 - 4182, XP008116172 *
DE, BK ET AL: "Protection against virulent H5 avian influenza virus infection in chickens by an inactivated vaccine produced with recombinant vaccinia virus", VACCINE, vol. 6, no. 3, June 1988 (1988-06-01), pages 257 - 261, XP023619192 *
MAASSAB ET AL: "The development of Live Attenuated Cold-adapted Influenza Virus Vaccine for Humans", REVIEWS IN MEDICAL VIROLOGY, vol. 9, 1999, pages 237 - 244, XP008115938 *
NEUMANN ET AL: "Reverse Genetics for the control of Avian Influenza", AVIAN DISEASES, vol. 47, 2003, pages 882 - 887, XP008116178 *
See also references of EP1766059A4 *

Also Published As

Publication number Publication date
EP1771552B1 (en) 2012-08-01
AU2005248375A1 (en) 2005-12-08
CA2568015C (en) 2013-08-27
EP1771552A2 (en) 2007-04-11
US20110052618A1 (en) 2011-03-03
US7504109B2 (en) 2009-03-17
EP2530147B1 (en) 2014-09-10
US20120034264A1 (en) 2012-02-09
JP4980896B2 (en) 2012-07-18
AU2005248375B2 (en) 2010-12-16
EP2530147A3 (en) 2013-02-27
ES2393492T3 (en) 2012-12-21
US8765136B2 (en) 2014-07-01
US20090175909A1 (en) 2009-07-09
AU2005248377A1 (en) 2005-12-08
JP4980895B2 (en) 2012-07-18
EP2465927B1 (en) 2014-12-24
EP1766059A2 (en) 2007-03-28
CA2879182A1 (en) 2005-12-08
US20060008473A1 (en) 2006-01-12
EP2522719A1 (en) 2012-11-14
EP2530147A2 (en) 2012-12-05
EP1766059A4 (en) 2010-03-31
EP2465927A1 (en) 2012-06-20
EP2902484A1 (en) 2015-08-05
EP1771552A4 (en) 2009-10-21
CA2879182C (en) 2017-02-14
WO2005116258A2 (en) 2005-12-08
WO2005116258A3 (en) 2007-02-01
ES2394033T3 (en) 2013-01-15
EP1766059B1 (en) 2012-07-11
CA2568020A1 (en) 2005-12-08
CA2568015A1 (en) 2005-12-08
AU2005248377B2 (en) 2011-03-24
AU2011201022A1 (en) 2011-03-31
HK1179648A1 (en) 2013-10-04
EP2522719B1 (en) 2013-12-25
ES2525672T3 (en) 2014-12-29
JP2008500042A (en) 2008-01-10
ES2454266T3 (en) 2014-04-10
ES2533382T3 (en) 2015-04-09
CA2568020C (en) 2015-04-07
US7981429B2 (en) 2011-07-19
US7527800B2 (en) 2009-05-05
WO2005116260A2 (en) 2005-12-08
US20050287172A1 (en) 2005-12-29
AU2011201022B2 (en) 2012-04-26
CA2822895A1 (en) 2005-12-08
US20090136530A1 (en) 2009-05-28
US7744901B2 (en) 2010-06-29
JP2008500041A (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2005116260A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2008021959A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2006098901A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2010006144A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2005018539A8 (en) Influenza hemagglutinin and neuraminidase variants
WO2008112017A3 (en) Avian influenza vaccine
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
PL1976559T6 (en) Influenza vaccines containing hemagglutinin and matrix proteins
MX2012000123A (en) Swine influenza hemagglutinin variants.
EP1603590A4 (en) Influenza virus vaccine
DK1732917T3 (en) Selected CGRP antagonists, processes for their preparation, and their use as a drug
DK3326673T3 (en) SPRAYERS, SPRAY INTERFACES AND SPRAY STAMPS FOR USE WITH MEDICAL INJECTORS
HK1134781A1 (en) Feline vaccines against avian influenza
EP3810634A4 (en) Mosaic influenza virus hemagglutinin polypeptides and uses thereof
AP2167A (en) Multivalent avian influenza vaccines.
WO2011019932A3 (en) Compositions and methods for the therapy and diagnosis of influenza
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
EA201290897A1 (en) VACCINES FOR PANDEMIC FLU
ZA200809056B (en) Influenza virus vaccine
WO2010093537A3 (en) Influenza hemagglutinin and neuraminidase variants
EP2097103A4 (en) Influenza vaccine formulation
EP1807116A4 (en) Influenza vaccination
DK1906921T3 (en) Clear pharmaceutical aqueous microemulsion comprising propofol and method of preparation
Yu Terms about Influenza A (H1N1)
Pettis Avian Flu

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2568020

Country of ref document: CA

Ref document number: 2007515200

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005248377

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005751982

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005248377

Country of ref document: AU

Date of ref document: 20050520

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005248377

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005751982

Country of ref document: EP